Prediction of the effects of gonadotropin-releasing hormone agonist therapy in uterine leiomyoma by T1 contrast-enhanced magnetic resonance imaging sequences

Slides:

Advertisements

Similar presentations

Prediction of the effects of gonadotropin-releasing hormone agonist therapy in uterine leiomyoma by T1 contrast-enhanced magnetic resonance imaging sequences

Advertisements

The Management of Uterine Leiomyomas

Kuhali Kundu, D.O., Arnold W. Cohen, M.D., Jay Goldberg, M.D.

Sachiko Matsuzaki, M. D. , Takashi Murakami, M. D. , Shigeki Uehara, M

Is the effect of premature elevated progesterone augmented by human chorionic gonadotropin versus gonadotropin-releasing hormone agonist trigger? Matthew.

Human chorionic gonadotropin administration does not increase plasma androgen levels in patients undergoing controlled ovarian hyperstimulation Renato.

Pituitary desensitization to gonadotropin-releasing hormone increases abdominal adiposity in hyperandrogenic anovulatory women Daniel A Dumesic, M.D.,

Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas Vera Grigorieva, MD, Mario Chen-Mok, PhD, Marina.

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Amber Samuel, M. D. , Fiona M. Fennessy, M. D. , Ph. D. , Clare M. C

Steven D Spandorfer, M. D. , F Arrendondo-Soberon, M. D. , J. R

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

Ultrasound-guided high-intensity focused ultrasound ablation for adenomyosis: the clinical experience of a single center Min Zhou, M.D., Ph.D., Jin-Yun.

Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist.

A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone.

Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix.

A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin)

Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata Ibrahim Sozen, M.D., Aydin Arici,

Effect of short-term hormone therapy on oxidative stress and endothelial function in African American and Caucasian postmenopausal women Raymond W Ke,

Reproductive aging and variability in the ovarian antral follicle count: application in the clinical setting Karl R Hansen, M.D., Ph.D., Jamie L Morris,

Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis

Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles Tsung-Hsien.

Prolonged gonadotropin-releasing hormone agonist therapy reduced expression of nitric oxide synthase in the endometrium of women with endometriosis and.

Microdose follicular phase gonadotropin-releasing hormone agonists (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization5

A remnant tubal pregnancy after cloacal malformation repair

Immunohistochemical analysis of the role of angiogenic status in the vasculature of peritoneal endometriosis Sachiko Matsuzaki, M.D., Michel Canis, M.D.,

Pelvic mass in a woman with Mayer-Rokitansky-Kuster-Hauser syndrome

Efficacy of tibolone as “add-back therapy” in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids Edward.

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled,

Nicolas Bourdel, M. D. , Toby Collins, Ph. D. , Daniel Pizarro, Ph. D

Robert F. Casper, M.D. Fertility and Sterility

Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain Mohamed A. Bedaiwy,

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

The Management of Uterine Leiomyomas

Increased progesterone receptor expression in uterine leiomyoma: correlation with age, number of leiomyomas, and clinical symptoms Anastasia Tsigkou,

Effects of photodynamic therapy using 5-aminolevulinic acid on cultured human adenomyosis-derived cells Haruka Suzuki-Kakisaka, M.D., Takashi Murakami,

Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis.

Bo Yu, M.D., Jane Ruman, M.D., Gregory Christman, M.D.

Administration of goserelin acetate after uterine artery embolization does not change the reduction rate and volume of uterine myomas George A. Vilos,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Successful pregnancy after oocyte activation by a calcium ionophore for a patient with recurrent intracytoplasmic sperm injection failure, with an assessment.

Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.

Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,

Small Lymphocytic Lymphoma Presenting with Hypopituitarism

Regulation of assisted reproductive technologies in the United States

Sperm to zona pellucida binding depends on the use of a gonadotropin-releasing hormone agonist or a gonadotropin-releasing hormone antagonist Annika.

Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men Subodhsingh Chauhan, M.D.,

Three-dimensional computed tomography combined with hysterosalpingography is useful for both diagnosis and treatment of iatrogenic diverticulum of the.

Intestinal endometriosis complicated by ileal perforation after initiation of gonadotropin- releasing hormone agonist therapy Sayaka Saito, M.D., Takashi.

Spontaneous pregnancy in a patient who was homozygous for the Q106R mutation in the gonadotropin-releasing hormone receptor gene Didier Dewailly, M.D.,

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization Efstratios M Kolibianakis, M.D., Kostas.

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

Effectiveness of short-term administration of tibolone plus gonadotropin-releasing hormone analogue on the surgical outcome of laparoscopic myomectomy

Concomitant treatment of severe uterine adenomyosis in a premenopausal woman with an aromatase inhibitor and a gonadotropin-releasing hormone agonist

Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human.

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation

Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study Ahmed Badawy, M.D., Aboubakr.

The gonadotropin-releasing hormone (GnRH)-1 gene, the GnRH receptor gene, and their promoters in patients with idiopathic hypogonadotropic hypogonadism.

Fertility and Sterility

Yukihiro Terada, M. D. , Sou-Ichi Nakamura, M. D. , Laura Hewitson, Ph

Increased pregnancy rates after ultralong postoperative therapy with gonadotropin- releasing hormone analogs in patients with endometriosis Dagmar Rickes,

Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle- stimulating hormone (FSH) in normoandrogenic ovulatory women.

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Where does the embryo implant after embryo transfer in humans?

Presentation transcript:

Prediction of the effects of gonadotropin-releasing hormone agonist therapy in uterine leiomyoma by T1 contrast-enhanced magnetic resonance imaging sequences Masahiro Kadowaki, M.D., Takashi Murakami, M.D., Ph.D., Junko Morita, M.D., Yukihiro Terada, M.D., Ph.D., Nobuo Yaegashi, M.D., Ph.D., Kunihiro Okamura, M.D., Ph.D. Fertility and Sterility Volume 77, Issue 5, Pages 1081-1082 (May 2002) DOI: 10.1016/S0015-0282(02)03062-5

FIGURE 1 Correlation between enhancement and reduction rates. The Spearman correlation coefficient and corresponding P value were .94 and <.001, respectively. The horizontal line represents a reduction rate of 0%. Myomas that became larger after GnRH agonist therapy appear below this line. Kadowaki. GnRH agonist effect in myoma. Fertil Steril 2002. Fertility and Sterility 2002 77, 1081-1082DOI: (10.1016/S0015-0282(02)03062-5)